Michael Benkowitz Sells 10,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $956,195.85. The trade was a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Michael Benkowitz also recently made the following trade(s):

• On Monday, February 10th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $348.06, for a total transaction of $3,480,600.00.
• On Monday, February 3rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $353.64, for a total transaction of $3,536,400.00.
• On Monday, January 27th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $370.71, for a total transaction of $3,707,100.00.
• On Tuesday, January 21st, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $364.91, for a total transaction of $3,649,100.00.
• On Monday, January 13th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $364.62, for a total transaction of $3,646,200.00.
• On Monday, December 30th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $356.68, for a total transaction of $3,566,800.00.
• On Monday, December 23rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $361.95, for a total transaction of $3,619,500.00.
• On Monday, November 25th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $372.75, for a total transaction of $3,727,500.00.

United Therapeutics Stock Performance

United Therapeutics stock opened at $380.78 on Thursday. The company’s fifty day moving average price is $362.58 and its 200 day moving average price is $359.89. United Therapeutics Co. has a 1 year low of $213.75 and a 1 year high of $417.82. The stock has a market capitalization of $17.00 billion, a P/E ratio of 16.72, a P/E/G ratio of 0.96 and a beta of 0.57.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently added to or reduced their stakes in UTHR. Newbridge Financial Services Group Inc. acquired a new stake in United Therapeutics in the 4th quarter valued at $25,000. Brooklyn Investment Group acquired a new stake in United Therapeutics in the 3rd quarter valued at $33,000. Dunhill Financial LLC grew its stake in United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 50 shares during the period. State of Wyoming acquired a new stake in United Therapeutics in the 4th quarter valued at $62,000. Finally, Millstone Evans Group LLC acquired a new stake in United Therapeutics in the 4th quarter valued at $67,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Argus increased their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Oppenheimer increased their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. The Goldman Sachs Group increased their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. Finally, LADENBURG THALM/SH SH increased their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $382.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.